Nolotil study reveals high risk for UK patients

Research in Alicante shows British nationals face a significantly higher risk of fatal agranulocytosis from metamizole than Spaniards.

A study presented at the Spanish Society of Hospital Pharmacy (SEFH) congress has highlighted a stark disparity in how patients react to metamizole, the active ingredient in the popular painkiller Nolotil. Analysing cases in the province of Alicante between 2016 and 2017, researchers identified nine deaths caused by metamizole-induced agranulocytosis. Of those who died, seven were British citizens and two were Spanish.

Agranulocytosis is a severe clinical condition involving a drastic reduction in granulocytes, a type of white blood cell essential for fighting infection. The research, based on a 2019 internal report from the Generalitat Valenciana, tracked 41 hospitalised patients across five health departments: Denia, Villajoyosa, Torrevieja, San Juan, and Orihuela. The patient group was predominantly international, consisting of 26 British nationals, 11 Spaniards, and individuals from Denmark, the Netherlands, Sweden, and Morocco.

A disproportionate impact on British patients

The data reveals a significant gap in risk levels between different nationalities. Among Spanish patients, the study calculated 0.33 cases of agranulocytosis per 100,000 defined daily doses (DDD), or 0.084 cases per 1,000 patients treated. In contrast, the rate for British patients—who numbered 62,000 residents in the study areas—soared to 39.8 cases per 100,000 DDD, representing 6.62 cases per 1,000 patients treated.

This vulnerability is further supported by recent clinical findings. A 2024 study published in the European Journal of Clinical Pharmacology found that agranulocytosis was more than four times more common with metamizole than with other analgesics used for pain and high fever.

Regulatory responses and safety warnings

Metamizole has a long history, having first been marketed in Germany in 1922. However, its safety profile has led to its withdrawal in several countries, including the United Kingdom, Ireland, the United States, France, Sweden, and Denmark. More recently, the European Medicines Agency (EMA) conducted a safety re-evaluation between 2023 and 2024 following the drug's withdrawal in Finland.

In Spain, the Spanish Agency for Medicines and Health Products (AEMPS) issued a note in 2018 recommending that metamizole should not be used for longer than one week. Despite these warnings, the drug remains available in Spain, even as evidence continues to mount regarding the specific risks it poses to certain populations.